New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease

WILMINGTON, Del.--(BUSINESS WIRE)--May 19, 2024--

Related Keywords

Japan ,Cambridge ,Cambridgeshire ,United Kingdom ,Manchester ,United States ,American ,America ,Lymphopoietin Isoforms ,Dave Singh ,Brendan Mcevoy ,Jillian Gonzales ,Sharon Barr ,Global Initiative On Obstructive Lung Disease ,Centers For Disease ,International Conference ,American Thoracic Society ,National Heart ,Amgen ,Astrazeneca ,American Lung Association ,University Of Manchester ,Blood Institute ,Global Initiative For Chronic Obstructive Lung Disease ,Confidence Interval ,Respiratory Pharmacology ,Executive Vice President ,Respiratory Questionnaire ,Asthma Symptoms ,Prescribing Information ,Patient Informationandinstructions ,Obstructive Pulmonary Disease ,North America ,Rare Diseases ,Thoracic Society ,Blood Eosinophil Count ,Global Initiative ,Chronic Obstructive Lung Disease ,Disease Control ,Leading Causes ,Learn More Breathe Better ,Ultimate Relationship ,One Year Mortality ,Their Predictors ,Patients Hospitalized ,Nationwide Population Based ,First Year After Hospitalization ,Chronic Obstructive Pulmonary ,Obstructive Lung Disease ,Atherosclerosis Risk ,Stromal Lymphopoietin Isoforms ,Inflammatory Disorders ,Business Wire ,